Browse diseases

…romising tool in predicting long-term outcomes in patients with NSCLC receiving curative-intent treatment. This highlights the import…

…this patient.Methods A 65 year-old Ex smoker male with advanced non-small cell lung cancer was found to have both high-level MET amplification and high PD…

…targetable barrier to immune infiltration in genetically ‘cold’ NSCLC. Pharmacologic GLUT1 inhibition reprograms the tumor microenvir…

…ive disease by D90. The patient with KRASG12V /STK11 co-mutated NSCLC who had progressed on carboplatin, pemetrexed, and pembrolizuma…

… 300 subjects with histologically confirmed advanced/metastatic NSCLC. Eligible participants must have received two prior lines of sy…

…bel, single-arm phase II clinical trial enrolling patients with NSCLC with PD-L1 tumor proportion score (22C3-IHC assay) ≥ 1% who hav…

…n most animals. As the majority of STK11-mutated cancers are in NSCLC, we sought to verify our findings in murine lung models. The co…

…ombination with pembrolizumab is ongoing in RAS mutant advanced NSCLC ( NCT06162221).…

…Background Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer cases, with EG…

…Introduction The benefits of prehab for lung cancer patients are accepted but services vary across England; with fi…

…ic changes in the tumor microenvironment (TME) in patients with non-small cell lung cancer (NSCLC) and acquired resistance to epidermal growth factor rece…

…blobar resection (segmentectomy or wedge) for clinical stage Ia NSCLC (<2 cm) were included in the random-effects meta-analyses. Risk…